Answers are grounded in this paper and cite their sources.
Finerenone in conjunction with SoC is a more cost-effective treatment alternative to SoC alone for adult patients with CKD and T2D from a Japanese healthcare payer perspective.
No takes yet. Share an insight, caveat, or question.
Igarashi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: